Close

VeriSIM Life Partners with Clarivate to Help Researchers Accelerate and De-Risk Drug Development

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

WHO Supplies Medical Equipment for Post-Marburg...

In a recent move, the World Health Organization has...

Life Sciences Sector Plan Sets UK...

Main Article: UK Life Sciences Sector Plan Sets Sights...

UK Government Launches Ambitious Life Sciences...

Government Unveils Life Sciences Roadmap for Growth and Innovation London,...

Highly Customized Treatments to Offer Specialized...

The Human Medicines Regulations 2025, which came into force...

VeriSIM Life, the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, announced a partnership with Clarivate, a global leader in connecting people and organizations to intelligence they can trust.

This collaboration combines VeriSIM Life’s unique approach to helping researchers make early and accurate predictions about compound safety and efficacy with Cortellis Drug Discovery IntelligenceTM by Clarivate, a leading source of pharma and drug research and development intelligence. Together these solutions will provide pharmaceutical and biotech companies with R&D insights to de-risk and accelerate drug discovery and avoid late-stage failures during clinical trials.

Researchers will benefit from VeriSIM Life’s BIOiSIM® platform, which leverages artificial intelligence (AI) and machine learning with mechanistic modeling to make early and accurate predictions about compound safety and efficacy. In addition, VeriSIM Life’s unique Translational Index™ technology can help determine which candidate is superior to others using hybrid AI technology, informing key stage-gate decisions and improving pre-clinical success rates.

“This collaboration will enable Clarivate customers to access VeriSIM’s powerful virtual drug development engine and deep expertise with our biosystem simulations,” said Dr. Jo Varshney, CEO of VeriSIM Life. “Our goal is to help our clients bring their therapies from bench to bedside faster and more efficiently. Partnering with Clarivate will allow life sciences companies to accomplish that objective by accessing world-class capabilities that provide researchers with the intelligence they need to develop treatments that improve patient lives.”

“Clarivate is committed to making life science intelligence universal and actionable,” said Gavin Coney, Vice President, Partnerships at Clarivate. “Working with the combination of Clarivate and VeriSIM Life will allow companies to benefit by gaining additional and valuable insights that can reduce risk, provide them with information to make more informed decisions with extraordinary accuracy, and bridge the translational gap between pre-clinical and clinical research. Ultimately, this partnership can bring life-saving treatments to patients more quickly.”

Clarivate is a leading global information services provider that connects people and organizations to intelligence they can trust to transform their perspective, their work and our world. Clarivate offers subscription- and technology-based solutions coupled with deep domain expertise and covering the areas of Academia & Government, Life Sciences & Healthcare and Intellectual Property.

Latest stories

Related stories

WHO Supplies Medical Equipment for Post-Marburg Virus Heal

In a recent move, the World Health Organization has...

Life Sciences Sector Plan Sets UK on Global Growth Track

Main Article: UK Life Sciences Sector Plan Sets Sights...

UK Government Launches Ambitious Life Sciences Sector Plan

Government Unveils Life Sciences Roadmap for Growth and Innovation London,...

Highly Customized Treatments to Offer Specialized Care to UK

The Human Medicines Regulations 2025, which came into force...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back